Today: 15 May 2026
Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight
15 May 2026
3 mins read

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

IRVINE, California, May 15, 2026, 03:02 PDT

  • Mobix Labs has entered into a non-binding letter of intent for the acquisition of Special Project Delivery, a U.S.-based platform focused on critical minerals and energy storage.
  • MOBX finished Thursday’s session at $3.11, a jump of 78.74%, with volume at 158.8 million shares.
  • The company bumped up the principal on a Leviston Resources convertible note to $4.0 million, pulling in roughly $833,000 in fresh cash.

Mobix Labs Inc. jumped into the rare-earth supply chain on Thursday, announcing it had entered a non-binding letter of intent to buy Special Project Delivery LLC, a private U.S. group with a focus on rare earth elements, critical minerals, and energy storage. Shares in Mobix Labs finished the session up 78.74% at $3.11, with trading volume hitting 158.8 million shares, per the company’s delayed Nasdaq data from LSEG.

Here’s the issue: rare earth elements—critical for magnets, electronics, and defense—remain deeply tied to Chinese supply chains, and Washington wants to change that. Tougher U.S. defense procurement rules kick in on Jan. 1, 2027, broadening restrictions to cover every step in the neodymium-iron-boron magnet supply chain, from raw mining to finished magnets.

The situation hasn’t stabilized yet. Jamieson Greer, the U.S. Trade Representative, noted some progress in rare-earth shipments from China to the U.S., though certain export licenses from Beijing are still dragging. “I would give them a passing grade,” Greer said in an interview with Bloomberg Television, according to Reuters on Friday. Reuters

Mobix said SPD was launched in 2019 out of Newport Beach, California, holding assets in critical minerals, energy storage, and Western U.S. water infrastructure. The letter of intent sets out an initial path for due diligence and negotiations on final terms, but neither party is obligated to complete a deal.

Mobix Labs chairman James Peterson, who previously led Microsemi, called rare earths and critical minerals “one of the defining competitive battlegrounds” for the coming decade. SPD CEO Paul Singarella said the deal would link SPD with a publicly listed defense and dual-use tech firm that’s already active in aerospace and defense sectors. Mobix Labs, Inc

Financing developments played a role in the investor response as well. Mobix disclosed an amended senior secured convertible note with Leviston Resources, lifting the principal to $4.0 million from $3.0 million. In exchange, Mobix is getting roughly $833,000 in extra cash. Convertible notes function as debt that may convert to equity under certain conditions.

Cash is a pressing issue here. Mobix’s 10-Q for the December quarter showed net revenue at $1.875 million—a 41% slide year-over-year—and a net loss of $10.125 million. As of Dec. 31, cash on hand had dwindled to $268,000. The company flagged “substantial doubt” about staying afloat without new funding.

Holders may also face pressure from financing moves. According to a May 7 prospectus, Leviston registered as many as 2.5 million shares for resale tied to the conversion of its promissory note—a chunk that would represent roughly 23.94% of outstanding Class A shares as of April 16, if all the shares hit the market, the filing said.

Mobix is stepping into a sector that’s already benefiting from substantial policy backing. Last year, MP Materials clinched a multibillion-dollar deal with the U.S. Defense Department to ramp up rare-earth magnet production—“a game changer” for the non-China market, according to Adamas Intelligence’s Ryan Castilloux. In March, Lynas Rare Earths unveiled a U.S. government supply arrangement for rare-earth oxides, with roughly $96 million in Pentagon purchases included. Reuters

Prediction-market odds highlight the uncertainty here. On Polymarket, traders are putting the chances of “rare earth export relief” for the U.S. tied to the Trump-Xi summit at just 26% by May 22, according to rules that call for an explicit announcement from China. The market isn’t limited to any one company, but it’s a clear signal that fast action still looks unlikely. Polymarket

Execution stands out as the key risk. The SPD letter isn’t binding—Mobix needs to hammer out terms and secure financing for any agreement. Its recent note amendment flagged another concern: conversions could hit current holders with more dilution, particularly if the share price drops and pushes the conversion price down, which would mean more new shares.

Mobix has had a bumpy ride on Nasdaq. Back in April, the company executed a 1-for-10 reverse split to get its share price up, and after that, Nasdaq confirmed Mobix was back in line with the $1 minimum bid requirement.

Right now, Mobix is seen more as a niche, leveraged bet on defense supply-chain reshoring than a full-fledged rare-earth player. Investors are watching for a few key developments: if SPD negotiations result in a binding deal, how Mobix plans to finance it, and whether the company can translate the critical minerals boom into steady revenue.

Stock Market Today

  • Key Advice for Investors: Focus on Long-Term Market Investment, Not Short-Term Fluctuations
    May 15, 2026, 6:19 AM EDT. The stock market has confounded many investors with strong returns despite economic challenges, including inflation and geopolitical tensions. The S&P 500 gained about 33% in the past year, the Dow rose roughly 23%, and the Nasdaq surged 47%. Experts caution against trying to predict short-term movements, which are highly volatile and influenced by unpredictable factors like trade tensions and supply disruptions. Historically, holding an investment such as an S&P 500 fund for longer periods significantly reduces the risk of losses. Short-term trading can result in locked-in losses and missed recovery gains, as illustrated by hypothetical scenarios involving the Vanguard S&P 500 ETF (VOO). Data shows one-year periods see negative returns 33% of the time, but this risk declines sharply over five- and ten-year horizons. Investors are advised to prioritize time in the market over timing it to enhance potential returns.

Latest articles

MRNO Stock Just Jumped Before the Bell. The Bigger Murano Global Test Is Still Ahead

MRNO Stock Just Jumped Before the Bell. The Bigger Murano Global Test Is Still Ahead

15 May 2026
Murano Global Investments shares surged 67% to $0.49 in U.S. premarket trading Friday on heavy volume, after weeks under pressure from debt issues and a Nasdaq listing warning. The stock closed at $0.29 Thursday and faces an Oct. 5 deadline to regain compliance with Nasdaq’s $1 minimum bid rule. Murano is late filing its annual report and has warned of “substantial doubt” about its ability to continue as a going concern.
Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

Mobix Labs Stock Soars 79% After Rare-Earth Deal Plan — Why MOBX Is Suddenly in the China Supply-Chain Fight

15 May 2026
Mobix Labs shares jumped 78.74% to $3.11 Thursday after it signed a non-binding letter of intent to acquire Special Project Delivery, a U.S. critical-minerals and energy-storage platform. The company also amended a convertible note with Leviston Resources, raising principal to $4 million for $833,000 in new cash. SPD was formed in 2019 and is based in Newport Beach, California.
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

15 May 2026
HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

MicroAlgo Stock Jumps Before The Bell As Quantum Circuit Algorithm Puts MLGO Back In Play

15 May 2026
MicroAlgo Inc. announced a new algorithm for automating quantum circuit design, sending its shares up 13.18% to $4.55 at Thursday’s close and 20.88% higher in pre-market trading Friday. The company said its tool can generate and evaluate quantum circuits without pre-set specs and tested it on standard problems, but did not disclose customers, pricing, or a launch date.
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus
Previous Story

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

MRNO Stock Just Jumped Before the Bell. The Bigger Murano Global Test Is Still Ahead
Next Story

MRNO Stock Just Jumped Before the Bell. The Bigger Murano Global Test Is Still Ahead

Go toTop